What the public record says

The current tracker records 9 public TGA actions relevant to the peptide and adjacent clinic-market trust problem. Monetary penalties and infringement notices visible in the tracker total at least $10,242,748, excluding the Your Solution Compounding Pharmacy undertaking because no penalty amount is attached to that public record.

What buyers should check

  • Peptide Clinics Pty Ltd remains the benchmark Australian peptide-advertising case because the Federal Court ordered a $10 million civil penalty.
  • Your Solution Compounding Pharmacy is included as an adjacent GLP-1 and compounded-weight-loss advertising undertaking, not a peptide-vendor fine.
  • The April 2024 Victorian case is the peptide-specific import infringement in this tracker.
  • The September 2025 Victorian case involved modafinil and armodafinil, not peptides, and is included as repeat personal-import enforcement context.
  • The December 2025 NSW case and January 2026 6-individual case are cosmetic-injectable and unapproved-therapeutic-goods enforcement context.
  • Switch Nutrition is included as therapeutic-goods advertising enforcement involving prohibited representations, not as a peptide vendor page.
  • The 2022 NSW medical-practitioner import case is included as a personal-import and prescription-only import warning, not a peptide-specific case.
  • Caruso's Natural Health is included because it shows mainstream listed-medicine sponsors can be penalised when evidence behind therapeutic uses is not held.
  • No vendor-specific TGA penalty is applied unless the vendor page links the public source directly.

Tracker table

Peptide Clinics Pty Ltd$10,000,000 Federal Court civil penalty

23 July 2019 - Peptide advertising and prescription-only medicines. Benchmark case for clinic-model peptide advertising and implied medical oversight.

TGA $10 million Peptide Clinics penalty
Your Solution Compounding PharmacyCourt-enforceable undertaking - no monetary penalty in source

2024 advertising period, undertaking published later - Compounded weight-loss medicine advertising. Clinic-model and GLP-1 advertising compliance context.

TGA Your Solution Compounding Pharmacy undertaking
Victorian individual$3,756 infringement notice

29 April 2024 - Peptide import infringement. Peptide-specific personal-import enforcement context.

TGA Victorian peptide import notice
Victorian individual, further notices$11,268 across 3 infringement notices

25 September 2025 - Prescription-only medicine import infringement. Repeat personal-import enforcement context; TGA names modafinil and armodafinil, not peptides.

TGA Victorian further notices
NSW-based individual$19,800 across 5 infringement notices

18 December 2025 - Cosmetic-injectable and prescription-only medicine import infringement. Adjacent import-risk context for injectables and unapproved prescription-only medicines.

TGA NSW cosmetic injectables import notice
6 individuals$43,560 across 11 infringement notices

29 January 2026 - Unapproved therapeutic-goods import and advertising infringement. Broader import, counterfeit, and unlawful advertising context for therapeutic goods.

TGA 6 individuals infringement notices
Switch Nutrition Pty Ltd$79,200 across 4 infringement notices

28 April 2026 - Therapeutic-goods advertising infringement. Advertising and prohibited-representation context for wellness and supplement-style claims.

TGA Switch Nutrition infringement notices
NSW-based medical practitioner$2,664 infringement notice

18 October 2022 - Prescription-only medicine import infringement. Personal-import and prescription-only medicine import context; not a peptide-specific case.

TGA NSW $2,664 import infringement
Caruso's Natural Health Pty Ltd$82,500 across 5 infringement notices

13 March 2024 - Listed-medicine evidence requirements. Mainstream sponsor evidence-context: even listed-medicine therapeutic-use claims need supporting evidence.

TGA Caruso's Natural Health infringement notices

Source links

Use this regulatory brief to ask better supplier questions. Do not convert a market-level warning into a vendor-specific claim unless the vendor page has a source attached.

Open vendor scorecards

Related regulatory briefs